Abstract
Resistance to antimony is a major cause of failure to therapy in a large proportion of visceral leishmaniasis cases. Methods to distinguish resistant and sensitive parasite are urgently needed as the standard in vitro intracellular drug susceptibility assays are cumbersome and time consuming. Differential expression profiling studies have led to the identification of several antimony resistance-associated genes; however, their efficacy as a potential biomarker for monitoring antimony resistance remains imprecise. We analysed the expression of eight genes [antimony metabolism-associated genes—multidrug resistance protein A (MRPA), γ-glutamylcysteine synthetase (γ-GCS) and aquaporin-1 (AQP1)—and genes identified by proteome/transcriptome profiling—heat shock protein 83, mitogen-activated protein kinase 1 and histones H1, H2A and H4) in antimony-resistant (n = 10) and antimony-sensitive (n = 4) clinical isolates of Leishmania donovani by quantitative real-time PCR, in comparison with a lab-generated resistant and a standard sensitive isolate. We observed a significant differential expression of MRPA, histone H1 (p < 0.01), γ-GCS, HSP83 (p < 0.005) and histone H2A and H4 (p < 0.0001) in a group of sodium antimony gluconate-resistant isolates compared to sensitive isolates. Preferential AQP1 expression was observed in all the sensitive isolates (p < 0.0001). Overall, expression profile in field isolates for all the genes studied showed altered expression in majority of isolates, while in some, the expression was static. All the isolates showed a mosaic of expression pattern of the genes analysed indicating constellation of genes contributes towards the drug susceptibility of parasite. As none of the genes exhibit an absolute correlation with phenotype, targeted expression analysis of a set of genes should be considered as biomarker for distinguishing the antimony-resistant and antimony-sensitive parasite.
Similar content being viewed by others
Abbreviations
- AQP1:
-
Aquaporin-1
- γ-GCS:
-
γ-Glutamylcysteine synthetase
- HSP83:
-
Heat shock protein 83
- MAPK1:
-
Mitogen-activated protein kinase 1
- MRPA:
-
Multidrug resistance protein A
- SAG:
-
Sodium antimony gluconate
References
Adaui V, Schnorbusch K, Zimic M, Gutiérrez A, Decuypere S, Vanaerschot M, DE Doncker S, Maes I, Llanos-Cuentas A, Chappuis F, Arévalo J, Dujardin JC (2011) Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony. Parasitology 138:183–193
Boer MD, Davidson RN (2006) Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 4:187–197
Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126
Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, Chappuis F, Dujardin JC (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 49:4616–4621
Decuypere S, Vanaerschot M, Rijal S, Yardley V, Maes L, de Doncker S, Chappuis F, Dujardin JC (2008) Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation. Parasitology 135:183–194
El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Papadopoulou B, Légaré D, Ouellette M (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 49:1988–1993
Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279:31010–31017
Haimeur A, Brochu C, Genest P, Papadopoulou B, Ouellette M (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 108:131–135
Kumar D, Kulshrestha A, Singh R, Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53:835–838
Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A (2010) Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol 70:609–617
Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180:564–567
Maharjan M, Singh S, Chatterjee M, Madhubala R (2008) Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani. Am J Trop Med Hyg 79:69–75
Mittal MK, Rai S, Ashutosh R, Gupta S, Sundar S, Goyal N (2007) Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76:681–688
Mukherjee A, Padmanabhan PK, Singh SM, Roy G, Girard I, Chatterjee M, Ouellette M, Madhubala R (2007) Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother 59:204–211
Mukherjee A, Roy G, Guimond C, Ouellette M (2009) The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants. Mol Microbiol 74:914–927
Ouellette M, Drummelsmith J, Papadopoulou B (2004) Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistant Update 7:257–266
Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F (2006) Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 9:26–39
Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG (2006) Resistance to antimony and treatment failure in human Leishmania Viannia infection. J Infect Dis 193:1375–1383
Singh N, Singh RT, Sundar S (2003) Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis 188:600–607
Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P (2006) Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis 194:302–306
Singh R, Kumar D, Duncan R, Nakhasi HL, Salotra P (2010) Over expression of histone H2A modulates drug susceptibility in L. donovani parasites. Int J Antimicrob Agents 36:50–57
Sreenivas G, Raju BV, Singh R, Selvapandiyan A, Duncan R, Sarkar D, Nakhasi HL, Salotra P (2004a) DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal leishmaniasis in humans. J Clin Microbiol 42:1739–1741
Sreenivas G, Singh R, Selvapandiyan A, Negi NS, Nakhasi HL, Salotra P (2004b) Arbitrary-primed PCR for genomic fingerprinting and identification of differentially regulated genes in Indian isolates of Leishmania donovani. Exp Parasitol 106:110–118
Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849–854
Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the centre of the Indian epidemic. Clin Infect Dis 31:1104–1106
Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R (2002) Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66:143–146
t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, Dujardin JC, Breitling R, Watson DG, Coombs GH, Decuypere S (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4:e904
Torres DC, Adaui V, Ribeiro-Alves M, Romero GA, Arévalo J, Cupolillo E, Dujardin JC (2010) Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes. Infect Genet Evol 10:727–733
Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M (2007) A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 6:88–101
Wiese M (2007) Leishmania MAP kinases—familiar proteins in an unusual context. Int J Parasitol 37:1053–1062
Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, Doncker SD, Ramirez L, Croft S, Arevalo J, Adaui V, Bermudez H, Decuypere S, Dujardin JC (2006) American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194:1168–1175
Acknowledgements
The authors are thankful to Jose M. Requena (Universidad Autonoma de Madrid, Spain) for anti-H2A antibodies. This work formed a part of PhD thesis of DK, submitted to BITS-Pilani, Rajasthan. Financial support of Indian Council of Medical Research, India is gratefully acknowledged. RS is a recipient of UNESCO L`oreal for Women in Science fellowship grant. DK and AK are grateful to the Council of Scientific and Industrial Research, India for fellowship.
Conflicts of interest
None to declare.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dhiraj Kumar and Ruchi Singh contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kumar, D., Singh, R., Bhandari, V. et al. Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani . Parasitol Res 111, 223–230 (2012). https://doi.org/10.1007/s00436-012-2823-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-012-2823-z